Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 321-325

  Van Wesenbeeck, L ^a   Rondelez, E ^a   Feyaerts, M ^a   Verheyen, A ^a   Van Der Borght, K ^a   Smits, V ^a   Cleybergh, C ^a   De Wolf, H ^a   Van Baelen, K ^a   Stuyver, L J ^a  

^a Tibotec Virco   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND G; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CROSS RESISTANCE; GENE MUTATION; GENOTYPE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RECOMBINANT;

HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES; QUINOLONES;

EID: 78650640149     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01733-09     Document Type: Article

References (20)

1. Al-Mawsawi, L. Q., R. I. Al-Safi, and N. Neamati. 2008. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin. Emerg. Drugs 13:213-225.
2. Canducci, F., M. Sampaolo, M. C. Marinozzi, E. Boeri, V. Spagnuolo, A. Galli, A. Castagna, A. Lazzarin, M. Clementi, and N. Gianotti. 2009. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23: 455-460.
3. Ceccherini-Silberstein, F., I. Malet, R. D'Arrigo, A. Antinori, A. G. Marcelin, and C. F. Perno. 2009. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 11:17-29.
4. Charpentier, C., M. Karmochkine, D. Laureillard, P. Tisserand, L. Belec, L. Weiss, A. Si-Mohamed, and C. Piketty. 2008. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 9:765-770.
5. Cooper, D. A., R. T. Steigbigel, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, H. Teppler, and B. Y. Nguyen. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
6. Delelis, O., K. Carayon, A. Saib, E. Deprez, and J. F. Mouscadet. 2008. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5:114.
7. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221.
8. Fransen, S., S. Gupta, R. Danovich, D. Hazuda, M. Miller, M. Witmer, C. J. Petropoulos, and W. Huang. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
9. Goethals, O., R. Clayton, M. Van Ginderen, I. Vereycken, E. Wagemans, P. Geluykens, K. Dockx, R. Strijbos, V. Smits, A. Vos, G. Meersseman, D. Jochmans, K. Vermeire, D. Schols, S. Hallenberger, and K. Hertogs. 2008. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 82:10366-10374.
10. Hicks, C., and R. M. Gulick. 2009. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48:931-939.
11. Jaskolski, M., J. N. Alexandratos, G. Bujacz, and A. Wlodawer. 2009. Piecing together the structure of retroviral integrase, an important target in AIDS therapy. FEBS J. 276:2926-2946.
12. Littel, R. C. 2002. Analysis of unbalanced mixed model data: a case study comparison of ANOVA versus REML/GLS. J. Agric. Biol. Environ. Stat. 7:472-490.
13. Malet, I., O. Delelis, M. A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J. F. Mouscadet, C. Katlama, V. Calvez, and A. G. Marcelin. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
14. McColl, D. J., and X. Chen. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 85:101-118.
15. Miller, M. 2007. Resistance to integrase inhibitors. J. HIV Ther. 12:101.
16. Min, S., I. Song, J. Borland, S. Chen, Y. Lou, T. Fujiwara, and S. C. Piscitelli. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
17. Sato, A., M. Kobayashi, T. Yoshinga, T. Fujiwara, M. Underwood, B. Johns, S. Foster, R. Hazen, R. Ferris, K. Brown, and E. Garvey. 2009. Abstr. 5th Int. AIDS Soc. Conf., abstr. WEPEA097.
18. Sichtig, N., S. Sierra, R. Kaiser, M. Daumer, S. Reuter, E. Schulter, A. Altmann, G. Fatkenheuer, U. Dittmer, H. Pfister, and S. Esser. 2009. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother. 64:25-32.
19. Vacca, J. P., J. S. Wai, E. F. Thorsten, M. W. Embrey, D. J. Hazuda, M. D. Miller, P. J. Felock, M. V. Witmer, L. J. Gabryelski, R. Anari, C. Kochansky, J. Ellis, and T. A. Lyde. 2007. Abstr. 4th Int. AIDS Soc. Conf., abstr. WEPEA088.
20. Van Baelen, K., E. Rondelez, V. Van Eygen, K. Arien, M. Clynhens, P. Van den Zegel, B. Winters, and L. J. Stuyver. 2009. A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J. Virol. Methods 161:231-239.